The effects of omega-3 supplementation in patients with Hashimoto's disease

Investigating the effects of omega-3 supplementation compared to placebo on anthropometric measurements, thyroid hormone and anti-tpo concentrations, and systemic inflammation in patients with Hashimoto's disease.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150815023617N7

Enrollment

Registered

2023-11-18

Start date

2023-12-01

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hashimoto's disease. Autoimmune thyroiditis

Interventions

Intervention 1: Intervention group: The group receiving omega-3 supplements should take two capsules of 1000 mg of omega-3 per day with the main meals of breakfast and dinner. Intervention 2: Control

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Willingness to cooperate diagnosed with Hashimoto's thyroidits (by endocrinologist) aged between 20-70 Body mass index between 25 - 35

Exclusion criteria

Exclusion criteria: Pregnancy or lactation Kidney disorders Following weight loss diets 3 months before the beginning of study Use of anti-coagulant agents, slimming and fat-burning drugs, fiber powder Presence of any blood clotting issues

Design outcomes

Primary

Measure	Time frame
High sensitivity C-reactive protein (hs-CRP). Timepoint: at the beginning and end of the study. Method of measurement: ELISA method.;Anti-thyroid peroxidase (Anti-TPO). Timepoint: at the beginning and end of the study. Method of measurement: ELISA method.;Thyroxine (T4). Timepoint: at the beginning and end of the study. Method of measurement: ELISA method.;Triiodothyronine (T3). Timepoint: at the beginning and end of the study. Method of measurement: ELISA method.;Thyroid Stimulating Hormone (TSH). Timepoint: at the beginning and end of the study. Method of measurement: ELISA method.;Waist circumference. Timepoint: at the beginning and end of the study. Method of measurement: measuring tape.;Hips circumference. Timepoint: at the beginning and end of the study. Method of measurement: measuring tape.;Waist to hips ratio. Timepoint: at the beginning and end of the study. Method of measurement: calculation.;Body Mass Index (BMI). Timepoint: at the beginning and end of the study. Method of measurement: Calculation based on the weight and height of the patient.	—

Measure

Time frame

High sensitivity C-reactive protein (hs-CRP). Timepoint: at the beginning and end of the study. Method of measurement: ELISA method.;Anti-thyroid peroxidase (Anti-TPO). Timepoint: at the beginning and end of the study. Method of measurement: ELISA method.;Thyroxine (T4). Timepoint: at the beginning and end of the study. Method of measurement: ELISA method.;Triiodothyronine (T3). Timepoint: at the beginning and end of the study. Method of measurement: ELISA method.;Thyroid Stimulating Hormone (TSH). Timepoint: at the beginning and end of the study. Method of measurement: ELISA method.;Waist circumference. Timepoint: at the beginning and end of the study. Method of measurement: measuring tape.;Hips circumference. Timepoint: at the beginning and end of the study. Method of measurement: measuring tape.;Waist to hips ratio. Timepoint: at the beginning and end of the study. Method of measurement: calculation.;Body Mass Index (BMI). Timepoint: at the beginning and end of the study. Method of measurement: Calculation based on the weight and height of the patient.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGolbon Sohrab

Shahid Beheshti University of Medical Sciences

golbonsohrab@sbmu.ac.ir+98 21 2207 7425

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026